Standard BioTools Inc. reported a total revenue of $21.1 million for the first quarter of 2026, reflecting a 5% increase from $20.2 million in the same period of 2025. The growth was primarily driven by a 35% rise in consumables revenue, which reached $11.0 million, while product revenue from instruments decreased by 33% to $4.5 million. The company also recorded a net income of $127.1 million, a significant turnaround from a net loss of $26.0 million in the prior year, largely due to a pre-tax gain of $172.3 million from the sale of its SomaScan Business.
In terms of operational changes, Standard BioTools completed the divestiture of its SomaScan Business to Illumina on January 30, 2026, for a total consideration of $388.2 million, which included cash and contingent earnout payments. This strategic move is part of the company's ongoing efforts to streamline operations and focus on its core mass cytometry and microfluidics businesses. The divestiture has allowed the company to improve its liquidity position, with cash and cash equivalents increasing to $265.8 million from $120.9 million at the end of 2025.
The company has also undergone significant restructuring, including a reduction in workforce that affected approximately 20% of its global staff. This restructuring is aimed at consolidating research and development capabilities and aligning operational costs with revenue projections. As a result, total operating expenses decreased by 37% to $23.8 million compared to the previous year, with notable reductions in research and development and selling, general, and administrative expenses.
Standard BioTools reported a total of 408,722 shares issued as of March 31, 2026, with an accumulated deficit of $1.1 billion. The company anticipates continued growth in consumables revenue as it expands its installed base and introduces new offerings. Looking ahead, Standard BioTools expects to leverage its enhanced liquidity and operational efficiencies to support future growth initiatives and improve its market position in the life sciences tools industry.
About STANDARD BIOTOOLS INC.
Standard BioTools Inc. develops and commercializes advanced life science tools in proteomics and genomics, including instruments, consumables, and services for biomedical research, drug discovery, and clinical applications. Its platforms—SomaScan, CyTOF, Hyperion, and Biomark—enable high-throughput, precise molecular analysis across diverse therapeutic areas. The company serves research institutions, biopharma, and clinical labs worldwide, leveraging proprietary technologies and strategic acquisitions to accelerate biological insights and health innovations.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.